Bristol-Myers Squibb to present Opdivo, Yervoy data at ESMO congress
Bristol-Myers Squibb announced new data across eight tumor types evaluating Opdivo and Yervoy as monotherapy or in combination, as well as new assets, to be presented at the 2016 European Society for Medical Oncology Congress in Copenhagen, Denmark from October 7-11. Data presented at this congress underscore the company's commitment to its portfolio and to discover the next wave of transformational Immuno-Oncology medicines, including combination therapies, for difficult-to-treat cancers. "Bristol-Myers Squibb continues to lead the scientific understanding of Immuno-Oncology with an extensive portfolio and a differentiated clinical development program where we have set a high bar of success to look for clear and differentiated improvements over currently available therapies," said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. "We remain focused on expanding the use of the Opdivo and Yervoy combination to more tumors, and bringing forward novel agents and combination regimens in earlier lines of therapy, to help even more patients with cancer."